These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

280 related items for PubMed ID: 30181415

  • 1. Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.
    Burkart J, Owen D, Shah MH, Abdel-Misih SRZ, Roychowdhury S, Wesolowski R, Haraldsdottir S, Reeser JW, Samorodnitsky E, Smith A, Konda B.
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
    [Abstract] [Full Text] [Related]

  • 2. BRAFV600E mutation: A promising target in colorectal neuroendocrine carcinoma.
    Dizdar L, Werner TA, Drusenheimer JC, Möhlendick B, Raba K, Boeck I, Anlauf M, Schott M, Göring W, Esposito I, Stoecklein NH, Knoefel WT, Krieg A.
    Int J Cancer; 2019 Mar 15; 144(6):1379-1390. PubMed ID: 30144031
    [Abstract] [Full Text] [Related]

  • 3. BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.
    Klempner SJ, Gershenhorn B, Tran P, Lee TK, Erlander MG, Gowen K, Schrock AB, Morosini D, Ross JS, Miller VA, Stephens PJ, Ou SH, Ali SM.
    Cancer Discov; 2016 Jun 15; 6(6):594-600. PubMed ID: 27048246
    [Abstract] [Full Text] [Related]

  • 4. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
    Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, Long GV, Nathan P, Ribas A, Flaherty K, Sun P, Legos JJ, McDowell DO, Mookerjee B, Schadendorf D, Robert C.
    Lancet Oncol; 2015 Oct 15; 16(13):1389-98. PubMed ID: 26433819
    [Abstract] [Full Text] [Related]

  • 5. Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report.
    Reyes R, Mayo-de-Las-Casas C, Teixidó C, Cabrera C, Marín E, Vollmer I, Jares P, Garzón M, Molina-Vila MÁ, Reguart N.
    Clin Lung Cancer; 2019 May 15; 20(3):e219-e223. PubMed ID: 30926357
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.
    Falkman L, Sundin A, Skogseid B, Botling J, Bernardo Y, Wallin G, Zhang L, Welin S, Lase I, Mollazadegan K, Crona J.
    Ups J Med Sci; 2024 May 15; 129():. PubMed ID: 38716076
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma.
    Marchand A, Tallet A, Collin C, Cormier B, Venel Y, Miquelestorena-Standley E, Machet L.
    Br J Dermatol; 2018 Aug 15; 179(2):528-529. PubMed ID: 29494756
    [No Abstract] [Full Text] [Related]

  • 11. Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
    Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E.
    Cancer Discov; 2018 Apr 15; 8(4):428-443. PubMed ID: 29431699
    [Abstract] [Full Text] [Related]

  • 12. Unbiased Proteomic and Phosphoproteomic Analysis Identifies Response Signatures and Novel Susceptibilities After Combined MEK and mTOR Inhibition in BRAFV600E Mutant Glioma.
    Maxwell MJ, Arnold A, Sweeney H, Chen L, Lih TM, Schnaubelt M, Eberhart CG, Rubens JA, Zhang H, Clark DJ, Raabe EH.
    Mol Cell Proteomics; 2021 Apr 15; 20():100123. PubMed ID: 34298159
    [Abstract] [Full Text] [Related]

  • 13. Successful treatment of occult pancreatic melanoma using BRAF/MEK inhibitors.
    Mizukami Y, Kanemaru H, Nakamura K, Hashigo S, Kajihara I, Miyashita A, Aoi J, Fukushima S, Honda Y, Ihn H.
    J Dermatol; 2020 Apr 15; 47(4):e126-e127. PubMed ID: 31872454
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Acquired resistance to BRAF inhibitors is mediated by BRAF splicing variants in BRAF V600E mutation-positive colorectal neuroendocrine carcinoma.
    Shimizu Y, Maruyama K, Suzuki M, Kawachi H, Low SK, Oh-Hara T, Takeuchi K, Fujita N, Nagayama S, Katayama R.
    Cancer Lett; 2022 Sep 01; 543():215799. PubMed ID: 35724767
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Resistance to BRAF-targeted therapy in melanoma.
    Sullivan RJ, Flaherty KT.
    Eur J Cancer; 2013 Apr 01; 49(6):1297-304. PubMed ID: 23290787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.